Resistance to treatment and heterogeneity of patients' response to therapy are two huge challenges in anticancer treatment. Understanding why patients differentially respond to treatment and how intracellular signaling mediates tumor resistance to therapy is crucial to improve the way we can stratify cancer patients for optimal therapy (i.e. precision oncology). This project has the goal to achieve a mechanistic understanding of multi-drug actions to rationally define personalised combinatorial treatment.
In this project you will work in a multidisciplinary team to combine innovative microfluidics technology for functional perturbation screening, with advanced mathematical modelling of cellular pathways mediating drug response, to improve our understanding of drug response in individual patients. This will allow understanding resistance mechanisms and provide a rational approach to design personalized combinatorial treatment strategies.
You will be embedded in the
Systems Biology for Oncology group and will work under the supervision of dr. Federica Eduati. The Systems Biology for Oncology group consists of a multidisciplinary and international team of researchers that study tumors as complex ecosystems composed of many interacting molecules and cells aimed at defining new types of effective biomarkers to improve precision oncology by taking a systems biology perspective. The group is part of the Department of Biomedical Engineering and the
Institute for Complex Molecular Systems (ICMS) and has both a dry and a wet lab component.
This position is part of the EuroTech PhD program, and you will spend at least six months in
Prof. Merten's group at EPFL - Laboratory of biomedical microfluidics (LBMM). The position will be focused on computational work to develop mathematical models (machine learning and mechanistic models) from transcriptomics and phenotypic data measured upon drug perturbations aimed at predicting patient's response to treatment. You will work in close collaboration with experimentalists from the Systems Biology for Oncology and the LBMM groups and with clinicians from the Catharina Hospital, and you will ideally be involved yourselves to some degree in data generation.